Inconsistent results regarding the association between low vitamin D level and hypertension (HTN) have led to uncertainty in clinical practice as to the use of vitamin D cutoff value. The aims of this study were to investigate the association between vitamin D deficiency and HTN in postmenopausal women and to determine the clinically significant cutoff value for vitamin D deficiency.
Methods:
We analyzed data from the Korean National Health and Nutrition Examination Survey 5 database (4107 postmenopausal women, aged 50–79 years). The cutoff value for vitamin D deficiency was based on the changes in parathyroid hormone (PTH) level according to serum 25(OH)D value.
Results:
PTH levels were significantly higher in groups with serum 25(OH)D <15 ng/mL (p < 0.001). When a serum 25(OH)D value of 15 ng/mL was used as a cutoff value, 35.2% of the subjects were found to be vitamin D deficient. Although the association between 25(OH)D level <15 ng/mL and systolic blood pressure did not remain significant after adjusting for season (p = 0.30), multiple logistic regression analysis revealed that 25(OH)D level <15 ng/mL was an independent risk factor for HTN (adjusted odds ratio [OR] 1.285, 95% confidence interval [CI] 1.024–1.614, p = 0.031).
Conclusions:
Using serum PTH level, we defined vitamin D deficiency as 25(OH)D <15 ng/mL in postmenopausal women. Vitamin D deficiency [25(OH)D <15 ng/mL] was a significant risk factor for HTN in postmenopausal women.
Get full access to this article
View all access options for this article.
References
1.
HolickMF. Vitamin D deficiency. N Engl J Med, 2007; 357:266–281.
2.
DobnigH, PilzS, ScharnaglH, et al.Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med, 2008; 168:1340–1349.
3.
GiovannucciE, LiuY, HollisBW, RimmEB. 25-hydroxyvitamin D and risk of myocardial infarction in men: A prospective study. Arch Intern Med, 2008; 168:1174–1180.
4.
ParkJK, LimYH, KimKS, et al.Body fat distribution after menopause and cardiovascular disease risk factors: Korean National Health and Nutrition Examination Survey 2010. J Womens Health, 2013; 22:587–594.
5.
TaddeiS. Blood pressure through aging and menopause. Climacteric, 2009; 12(Suppl 1):36–40.
6.
ParkJK, LimYH, KimKS, et al.Changes in body fat distribution through menopause increase blood pressure independently of total body fat in middle-aged women: The Korean National Health and Nutrition Examination Survey 2007–2010. Hypertens Res, 2013; 36:444–449.
7.
VaidyaA, FormanJP. Vitamin D and hypertension: Current evidence and future directions. Hypertension, 2010; 56:774–779.
8.
ScraggR, SowersM, BellC. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens, 2007; 20:713–719.
9.
HintzpeterB, MensinkGB, ThierfelderW, MullerMJ, Scheidt-NaveC. Vitamin D status and health correlates among German adults. Eur J Clin Nutr, 2008; 62:1079–1089.
10.
HypponenE, BoucherBJ, BerryDJ, PowerC. 25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: A cross-sectional study in the 1958 British Birth Cohort. Diabetes, 2008; 57:298–305.
11.
PittasAG, ChungM, TrikalinosT, et al.Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med, 2010; 152:307–314.
12.
WithamMD, NadirMA, StruthersAD. Effect of vitamin D on blood pressure: A systematic review and meta-analysis. J Hypertens, 2009; 27:1948–1954.
13.
BeveridgeLA, StruthersAD, KhanF, et al.Effect of Vitamin D supplementation on blood pressure: A systematic review and meta-analysis incorporating individual patient data. JAMA Intern Med, 2015; 175:745–754.
14.
MargolisKL, RayRM, Van HornL, et al.Effect of calcium and vitamin D supplementation on blood pressure: The Women's Health Initiative Randomized Trial. Hypertension, 2008; 52:847–855.
15.
LiL, YinX, YaoC, ZhuX, WuX. Vitamin D, parathyroid hormone and their associations with hypertension in a Chinese population. PloS One, 2012; 7:e43344.
16.
ChanR, ChanD, WooJ, et al.Serum 25-hydroxyvitamin D and parathyroid hormone levels in relation to blood pressure in a cross-sectional study in older Chinese men. J Hum Hypertens, 2012; 26:20–27.
17.
ChoYS, GoMJ, KimYJ, et al.A large-scale genome-wide association study of Asian populations uncovers genetic factors influencing eight quantitative traits. Nat Genet, 2009; 41:527–534.
18.
HongKW, JinHS, LimJE, KimS, GoMJ, OhB. Recapitulation of two genomewide association studies on blood pressure and essential hypertension in the Korean population. J Hum Genet, 2010; 55:336–341.
19.
OlsonS, WangMG, CarafoliE, StrehlerEE, McBrideOW. Localization of two genes encoding plasma membrane Ca2(+)-transporting ATPases to human chromosomes 1q25–32 and 12q21–23. Genomics, 1991; 9:629–641.
20.
GlendenningP, RatajczakT, PrinceRL, GaramszegiN, StrehlerEE. The promoter region of the human PMCA1 gene mediates transcriptional downregulation by 1,25-dihydroxyvitamin D(3). Biochem Biophys Res Commun, 2000; 277:722–728.
21.
VimaleswaranKS, CavadinoA, BerryDJ, et al.Association of vitamin D status with arterial blood pressure and hypertension risk: A mendelian randomisation study. Lancet Diabetes Endocrinol, 2014; 2:719–729.
22.
HagenauT, VestR, GisselTN, et al.Global vitamin D levels in relation to age, gender, skin pigmentation and latitude: An ecologic meta-regression analysis. Osteoporos Int, 2009; 20:133–140.
23.
HolickMF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc, 2006; 81:353–373.
24.
RosenCJ. Clinical practice: Vitamin D insufficiency. N Engl J Med, 2011; 364:248–254.
25.
KweonS, KimY, JangM-j, et al.Data resource profile: The Korea National Health and Nutrition Examination Survey (KNHANES). Int J Epidemiol, 2014; 43:69–77.
26.
LevinA, BakrisGL, MolitchM, et al.Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int, 2007; 71:31–38.
27.
ThomasMK, Lloyd-JonesDM, ThadhaniRI, et al.Hypovitaminosis D in medical inpatients. N Engl J Med, 1998; 338:777–783.
28.
Mozaffari-KhosraviH, LoloeiS, MirjaliliMR, BarzegarK. The effect of vitamin D supplementation on blood pressure in patients with elevated blood pressure and vitamin D deficiency: A randomized, double-blind, placebo-controlled trial. Blood Press Monitor, 2015; 20:83–89.
29.
Dawson-HughesB, MithalA, BonjourJP, et al.IOF position statement: Vitamin D recommendations for older adults. Osteoporos Int, 2010; 21:1151–1154.
30.
McKennaMJ, FreaneyR. Secondary hyperparathyroidism in the elderly: Means to defining hypovitaminosis D. Osteoporos Int, 1998; 8:S3–6.
31.
HolickMF, SirisES, BinkleyN, et al.Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab, 2005; 90:3215–3224.
32.
ValcourA, BlockiF, HawkinsDM, RaoSD. Effects of age and serum 25-OH-vitamin D on serum parathyroid hormone levels. J Clin Endocrinol Metab, 2012; 97:3989–3995.
33.
LevyD, EhretGB, RiceK, et al.Genome-wide association study of blood pressure and hypertension. Nat Genet, 2009; 41:677–687.
34.
JuddSE, RaiserSN, KumariM, TangprichaV. 1,25-dihydroxyvitamin D3 reduces systolic blood pressure in hypertensive adults: A pilot feasibility study. J Steroid Biochem Mol Biol, 2010; 121:445–447.
35.
AroraP, SongY, DusekJ, et al.Vitamin D therapy in individuals with prehypertension or hypertension: The DAYLIGHT trial. Circulation, 2015; 131:254–262.
36.
PfeiferM, BegerowB, MinneHW, NachtigallD, HansenC. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab, 2001; 86:1633–1637.
37.
LiYC, KongJ, WeiM, ChenZF, LiuSQ, CaoLP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest, 2002; 110:229–238.
38.
ZhaoG, FordES, LiC, Kris-EthertonPM, EthertonTD, BalluzLS. Independent associations of serum concentrations of 25-hydroxyvitamin D and parathyroid hormone with blood pressure among US adults. J Hypertens, 2010; 28:1821–1828.
39.
HeJL, ScraggRK. Vitamin D, parathyroid hormone, and blood pressure in the National Health and Nutrition Examination Surveys. Am J Hypertens, 2011; 24:911–917.
40.
TaylorEN, CurhanGC, FormanJP. Parathyroid hormone and the risk of incident hypertension. J Hypertens, 2008; 26:1390–1394.
41.
PepeJ, RomagnoliE, NofroniI, et al.Vitamin D status as the major factor determining the circulating levels of parathyroid hormone: A study in normal subjects. Osteoporos Int, 2005; 16:805–812.
42.
ZemelMB. Calcium modulation of hypertension and obesity: Mechanisms and implications. J Am Coll Nutr, 2001; 20:428S–435S; discussion 440S–442S.
43.
RashidG, BernheimJ, GreenJ, BenchetritS. Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways. Am J Physiol Renal Physiol, 2007; 292:F1215–1218.
Clavel-ChapelonF, Dormoy-MortierN. A validation study on status and age of natural menopause reported in the E3N cohort. Maturitas, 1998; 29:99–103.
46.
CarterGD, CarterR, JonesJ, BerryJ. How accurate are assays for 25-hydroxyvitamin D? Data from the international vitamin D external quality assessment scheme. Clin Chem, 2004; 50:2195–2197.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
